Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L, Pietilä EA, Turunen SP, Corvigno S, Hjerpe E, Bulanova D, Joneborg U, Alkasalias T, Miki Y, Yashiro M, Chernenko A, Jukonen J, Singh M, Dahlstrand H, Carlson JW, Lehti K.
Moyano-Galceran L, et al. Among authors: hjerpe e.
EMBO Mol Med. 2020 Apr 7;12(4):e11177. doi: 10.15252/emmm.201911177. Epub 2020 Mar 2.
EMBO Mol Med. 2020.
PMID: 32115889
Free PMC article.